Fig. 1.

Schematic outline of the in vivo studies. (A) 8–9- and 17-week old female GFP Ob⁺ mice (n = 4/group) received 30 mg/kg Cabozantinib (CBZ) or sterile H₂O control (CTRL) 5 × weekly for 5 days via oral gavage. Animals were killed 24 h after the last treatment administration. (B) Male and female 6-week old BALB/c nude as well as 9-week old female GFP Ob⁺ mice (n = 4–5/group) received 8 doses of 30 mg/kg CBZ or sterile H₂O control (CTRL). Animals were killed 6 h after the last administration. To monitor if treatment effects of CBZ were maintained once treatment was terminated additional female BALB/c nude mice were culled 5 (day 15) and 12 days (day 22) after treatment termination.